Links for fulltext
     (May Require Subscription)
Supplementary

Article: High-intensity focused ultrasound for hepatocellular carcinoma: A single-center experience

TitleHigh-intensity focused ultrasound for hepatocellular carcinoma: A single-center experience
Authors
Issue Date2011
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.annalsofsurgery.com
Citation
Annals Of Surgery, 2011, v. 253 n. 5, p. 981-987 How to Cite?
AbstractObjective: This study aims to evaluate the outcome of patients with hepatocellular carcinoma (HCC) treated by high-intensity focused ultrasound (HIFU) in a single tertiary referral center. Background: HIFU is the latest developed local ablation technique for unresectable HCC. The initial experience on its efficacy is promising, but the survival benefit of patients undergoing HIFU for HCC is poorly defined. Methods: From October 2006 to December 2008, 49 patients received HIFU for unresectable HCC. Each patient underwent a single session of HIFU with a curative intent. Treatment efficacy and survival outcome were evaluated. Clinicopathologic factors affecting the primary technique effectiveness and overall survival rates were investigated by univariate analysis. Results: The median size of the treated tumors was 2.2 cm, ranging from 0.9 to 8 cm. The majority of patients had single tumors (n = 41, 83.6%). Thirty-one patients (63.2%) had artificial right pleural effusion during HIFU treatment to reduce damage to the lung and diaphragm. The hospital mortality rate was 2% (n = 1) and the complication rate was 8.1% (n = 4). The primary technique effectiveness rate was 79.5% (39 of 49 patients). It increased from 66.6% in the initial series to 89.2% in the last 28 patients. Tumor size (3.0 cm) was the significant risk factor affecting the complete ablation rate. The 1- and 3-year overall survival rates were 87.7% and 62.4%, respectively. Child-Pugh liver function grading was the significant prognostic factor influencing the overall survival rate. Conclusions: HIFU is an effective treatment modality for unresectable HCC with a high technique effectiveness rate and favorable survival outcome. © 2011 Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/135541
ISSN
2014 Impact Factor: 8.327
2014 SCImago Journal Rankings: 3.819
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNg, KKCen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorChan, SCen_HK
dc.contributor.authorChok, KSHen_HK
dc.contributor.authorCheung, TTen_HK
dc.contributor.authorTung, Hen_HK
dc.contributor.authorChu, Fen_HK
dc.contributor.authorTso, WKen_HK
dc.contributor.authorYu, WCen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2011-07-27T01:36:46Z-
dc.date.available2011-07-27T01:36:46Z-
dc.date.issued2011en_HK
dc.identifier.citationAnnals Of Surgery, 2011, v. 253 n. 5, p. 981-987en_HK
dc.identifier.issn0003-4932en_HK
dc.identifier.urihttp://hdl.handle.net/10722/135541-
dc.description.abstractObjective: This study aims to evaluate the outcome of patients with hepatocellular carcinoma (HCC) treated by high-intensity focused ultrasound (HIFU) in a single tertiary referral center. Background: HIFU is the latest developed local ablation technique for unresectable HCC. The initial experience on its efficacy is promising, but the survival benefit of patients undergoing HIFU for HCC is poorly defined. Methods: From October 2006 to December 2008, 49 patients received HIFU for unresectable HCC. Each patient underwent a single session of HIFU with a curative intent. Treatment efficacy and survival outcome were evaluated. Clinicopathologic factors affecting the primary technique effectiveness and overall survival rates were investigated by univariate analysis. Results: The median size of the treated tumors was 2.2 cm, ranging from 0.9 to 8 cm. The majority of patients had single tumors (n = 41, 83.6%). Thirty-one patients (63.2%) had artificial right pleural effusion during HIFU treatment to reduce damage to the lung and diaphragm. The hospital mortality rate was 2% (n = 1) and the complication rate was 8.1% (n = 4). The primary technique effectiveness rate was 79.5% (39 of 49 patients). It increased from 66.6% in the initial series to 89.2% in the last 28 patients. Tumor size (3.0 cm) was the significant risk factor affecting the complete ablation rate. The 1- and 3-year overall survival rates were 87.7% and 62.4%, respectively. Child-Pugh liver function grading was the significant prognostic factor influencing the overall survival rate. Conclusions: HIFU is an effective treatment modality for unresectable HCC with a high technique effectiveness rate and favorable survival outcome. © 2011 Lippincott Williams & Wilkins.en_HK
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.annalsofsurgery.comen_HK
dc.relation.ispartofAnnals of Surgeryen_HK
dc.rightsThis is a non-final version of an article published in final form in Annals of Surgery, 2011, v. 253 n. 5, p. 981-987-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshCarcinoma, Hepatocellular - mortality - pathology - therapy-
dc.subject.meshCohort Studies-
dc.subject.meshHigh-Intensity Focused Ultrasound Ablation - methods-
dc.subject.meshLiver Neoplasms - mortality - pathology - therapy-
dc.subject.meshPalliative Care-
dc.titleHigh-intensity focused ultrasound for hepatocellular carcinoma: A single-center experienceen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0003-4932&volume=253&issue=5&spage=981&epage=987&date=2011&atitle=High-intensity+focused+ultrasound+for+hepatocellular+carcinoma:+a+single-center+experience-
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityChan, SC=rp01568en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturepostprint-
dc.identifier.doi10.1097/SLA.0b013e3182128a8ben_HK
dc.identifier.pmid21394012-
dc.identifier.scopuseid_2-s2.0-79954631974en_HK
dc.identifier.hkuros187648en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79954631974&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume253en_HK
dc.identifier.issue5en_HK
dc.identifier.spage981en_HK
dc.identifier.epage987en_HK
dc.identifier.isiWOS:000289510600021-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridNg, KKC=35248894000en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridChan, SC=7404255575en_HK
dc.identifier.scopusauthoridChok, KSH=6508229426en_HK
dc.identifier.scopusauthoridCheung, TT=7103334165en_HK
dc.identifier.scopusauthoridTung, H=23089742300en_HK
dc.identifier.scopusauthoridChu, F=7201881037en_HK
dc.identifier.scopusauthoridTso, WK=7006905486en_HK
dc.identifier.scopusauthoridYu, WC=37022285400en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats